Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel ...

StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the medical research ...

Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary ...

Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology firm specializing in biological products with a current market capitalization of $5.5 million, announced the appointment of Norman Staskey as its ...

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply ...

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Organovo Holdings ( (ONVO) ) has issued an announcement.

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease ...

Organovo Holdings, Inc. appointed Norman Staskey as the new President, Chief Financial Officer, and Principal Financial Officer following the resignation of Tomas Hess, who left to pursue retirement.